2 weeks Ago By ABMN Staff
Summit Investment Advisors Inc. cut its holdings in ResMed Inc. ( NYSE:RMD – Free Report ) by 3.
9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,430 shares of the medical equipment provider’s stock after selling 58 shares during the period. Summit Investment Advisors Inc.
’s holdings in ResMed were worth $327,000 at the end of the most recent reporting period. Several other institutional investors have also added to or reduced their stakes in the business. First Horizon Advisors Inc.
lifted its stake in shares of ResMed by 285.1% in the 4th quarter. First Horizon Advisors Inc.
now owns 593 shares of the medical equipment provider’s stock valued at $136,000 after acquiring an additional 439 shares during the last quarter. Peak Financial Advisors LLC purchased a new position in ResMed in the 4th quarter worth approximately $2,972,000. Principal Financial Group Inc.
lifted its position in ResMed by 2.9% in the third quarter. Principal Financial Group Inc.
now owns 186,776 shares of the medical equipment provider’s stock valued at $45,596,000 after purchasing an additional 5,284 shares during the last quarter. Spire Wealth Management boosted its stake in shares of ResMed by 11.3% during the fourth quarter.
Spire Wealth Management now owns 10,800 shares of the medical equipment provider’s stock valued at $2,470,000 after purchasing an additional 1,100 shares during the period. Finally, Asset Management One Co. Ltd.
grew its holdings in shares of ResMed by 2.8% in the fourth quarter. Asset Management One Co.
Ltd. now owns 60,489 shares of the medical equipment provider’s stock worth $14,105,000 after purchasing an additional 1,629 shares during the last quarter. 54.
98% of the stock is currently owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of equities research analysts recently commented on RMD shares. StockNews.
com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, April 15th. Stifel Nicolaus lowered their price objective on shares of ResMed from $250.00 to $240.
00 and set a “hold” rating for the company in a research note on Wednesday, March 5th. KeyCorp increased their target price on shares of ResMed from $266.00 to $280.
00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Mizuho set a $265.00 price target on ResMed in a report on Wednesday.
Finally, Piper Sandler increased their price objective on ResMed from $252.00 to $260.00 and gave the stock a “neutral” rating in a report on Friday, January 31st.
One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $251.
00. ResMed Stock Performance Shares of RMD stock opened at $212.89 on Monday.
The company’s fifty day moving average price is $223.12 and its 200-day moving average price is $234.46.
The stock has a market cap of $31.27 billion, a PE ratio of 25.13, a price-to-earnings-growth ratio of 1.
53 and a beta of 0.75. The company has a current ratio of 3.
33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13.
ResMed Inc. has a 12 month low of $178.49 and a 12 month high of $263.
05. ResMed ( NYSE:RMD – Get Free Report ) last posted its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.
43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14.
ResMed had a net margin of 25.34% and a return on equity of 26.17%.
On average, equities analysts expect that ResMed Inc. will post 9.47 EPS for the current fiscal year.
ResMed Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 13th were given a dividend of $0.53 per share.
This represents a $2.12 dividend on an annualized basis and a yield of 1.00%.
The ex-dividend date of this dividend was Thursday, February 13th. ResMed’s dividend payout ratio (DPR) is presently 25.03%.
Insider Buying and Selling at ResMed In related news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $219.
74, for a total transaction of $439,480.00. Following the sale, the director now directly owns 73,218 shares of the company’s stock, valued at approximately $16,088,923.
32. This represents a 2.66 % decrease in their position.
The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Also, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction dated Friday, February 7th.
The stock was sold at an average price of $236.77, for a total transaction of $1,896,290.93.
Following the completion of the transaction, the chief executive officer now directly owns 455,472 shares of the company’s stock, valued at $107,842,105.44. This trade represents a 1.
73 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Over the last 90 days, insiders sold 49,013 shares of company stock worth $11,298,816.
0.71% of the stock is owned by insiders. ResMed Company Profile ( Free Report ) ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets.
The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. See Also Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for ResMed Inc. ( NYSE:RMD – Free Report ). Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.
com's FREE daily email newsletter ..
